Brainstorm Cell Therapeutics, Inc. (BCLI)
0.9302
-0.07
(-6.98%)
USD |
OTCM |
Oct 02, 16:00
Brainstorm Cell Therapeutics Net Income (Quarterly) : -3.855M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.855M |
| March 31, 2026 | -2.127M |
| December 31, 2025 | -2.434M |
| September 30, 2025 | -2.106M |
| June 30, 2025 | -2.903M |
| March 31, 2025 | -2.864M |
| December 31, 2024 | -2.973M |
| September 30, 2024 | -2.708M |
| June 30, 2024 | -2.541M |
| March 31, 2024 | -3.401M |
| December 31, 2023 | -5.578M |
| September 30, 2023 | -1.226M |
| June 30, 2023 | -5.329M |
| March 31, 2023 | -5.059M |
| December 31, 2022 | -5.018M |
| September 30, 2022 | -6.858M |
| June 30, 2022 | -7.041M |
| March 31, 2022 | -5.36M |
| December 31, 2021 | -6.19M |
| September 30, 2021 | -5.336M |
| June 30, 2021 | -6.269M |
| March 31, 2021 | -6.662M |
| December 31, 2020 | -11.82M |
| September 30, 2020 | -4.488M |
| June 30, 2020 | -7.394M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.114M |
| December 31, 2019 | -7.692M |
| September 30, 2019 | -5.634M |
| June 30, 2019 | -4.90M |
| March 31, 2019 | -5.027M |
| December 31, 2018 | -5.383M |
| September 30, 2018 | -3.176M |
| June 30, 2018 | -3.091M |
| March 31, 2018 | -2.298M |
| December 31, 2017 | 0.276M |
| September 30, 2017 | -2.403M |
| June 30, 2017 | -1.04M |
| March 31, 2017 | -1.785M |
| December 31, 2016 | -0.624M |
| September 30, 2016 | -1.606M |
| June 30, 2016 | -0.962M |
| March 31, 2016 | -1.79M |
| December 31, 2015 | -1.384M |
| September 30, 2015 | -2.603M |
| June 30, 2015 | -2.265M |
| March 31, 2015 | -2.236M |
| December 31, 2014 | -2.73M |
| September 30, 2014 | -2.421M |
| June 30, 2014 | -1.984M |
| March 31, 2014 | -2.111M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0858M |
| Summit Therapeutics, Inc. | -215.70M |
| Kezar Life Sciences, Inc. | -5.756M |
| Protara Therapeutics, Inc. | -21.67M |
| Clene, Inc. | -13.42M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.855M |
| EPS Diluted (Quarterly) | -0.3494 |
| Enterprise Value | 11.62M |
| Earnings Yield | -102.6% |
| Normalized Earnings Yield | -102.56 |